Accurate Identification of Sepsis using SeptiCyte® RAPID and Comparison with other Biomarkers Presented at Society of Critical Care Medicine Critical Care Congress 2024

Immunexpress - the signature diagnostics for sepsis

This press release was first published at PR Newswire SEATTLE and BRISBANE, Australia, Jan. 22, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced  that data validating the use of SeptiCyte® RAPID in differentiating sepsis from systemic inflammatory response syndrome (SIRS) was selected for presentation on Sunday, January 21, during…

Read More

Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy

Immunexpress - the signature diagnostics for sepsis

SeptiCyte® RAPID may aid clinicians in determining early antibiotic administration and in bundle compliance for immunocompromised patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Nov. 17, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation validating the utility of SeptiCyte® RAPID…

Read More

Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID®

Immunexpress.com

EDTA blood collection tubes are used routinely in clinical settings for hematology procedures around the world SEATTLE and BRISBANE, Australia, Jan. 4, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug…

Read More

SeptiCyte RAPID® By Immunexpress Receives Regulatory Clearance from Australian Therapeutic Goods Administration (TGA)

Cision PR Newswire

The Cost of Sepsis in Australia report (2021) estimated that there are >90,000 sepsis cases in Australia each year and estimated direct and indirect costs of $700 million and $4 billion respectively SEATTLE and BRISBANE, Australia, Jan. 17, 2024 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis…

Read More

CHEST 2023 Poster Demonstrates the Utility of SeptiCyte® RAPID in Antibiotic Administration and Sepsis Bundle Compliance

This official press release was first published on PRNewswire SeptiCyte® RAPID may aid clinicians in making a determination on early antibiotic administration and in bundle compliance for patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Oct. 2, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected…

Read More

SeptiCyte® RAPID Receives ICD-10-PCS Code from the U.S. Centers for Medicare & Medicaid Services (CMS)

Immunexpress - the signature diagnostics for sepsis

This post originally appeared on Cision PR Newswire ICD-10-PCS code to provide accurate documentation of sepsis diagnosis for medical claims using SeptiCyte® RAPID SEATTLE and BRISBANE, Australia, Sept. 6, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has…

Read More

Immunexpress Announces Adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas

SEATTLE and BRISBANE, Australia, July 20, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for patients suspected of sepsis, announced today the adoption of SeptiCyte® RAPID by FirstHealth of the Carolinas, a non-profit health system licensed for four hospitals in Pinehurst, Troy, Rockingham and Raeford, North Carolina. SeptiCyte RAPID will be available at FirstHealth as a tool in differentiating…

Read More

Immunexpress and University Hospitals Cleveland Medical Center Present Quality Improvement Feasibility with SeptiCyte® RAPID at the 2023 American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo

Immunexpress - the signature diagnostics for sepsis

Immunexpress, Inc. 25 Jul, 2023, 16:30 ET SeptiCyte® RAPID, an in vitro diagnostic test intended to aid differentiating infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis, demonstrated good analytical performance SEATTLE and BRISBANE, Australia, July 25, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected…

Read More

Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis

Cision PR Newswire

This post originally appeared on Cision PR Newswire SEATTLE and BRISBANE, Australia, April 5, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID as a tool to determine…

Read More

New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients

SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients,…

Read More